By: Jarrett Barnhill, MD, DFAPA, FAACAP, NADD-CC.
In recent years advances in the neurosciences suggest a more complex view of behavioral and neuropsychiatric disorders among individuals with developmental disabilities. For many, traditional psychopharmacology raises the specter of untoward side effects or treatment nonresponse. Families frequently turn to alternative treatments as a solution. Unfortunately these decisions are made without an awareness of contradictory scientific evidence or potential complications when combined with psychotropics and other medical treatments. This presentation focuses on omega-3 fatty acids, melatonin, and a more recent addition, n-acetly cysteine, in the treatment.
Produced in 2012